id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-282312-h3h6vw5l	Greco, Antonio	Outcomes of renin–angiotensin–aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis	2020-07-16		.txt	text/plain	872	54	52	1 COVID-19 is associated with higher case fatality in patients with comorbidities, including those with arterial hypertension or other cardiovascular diseases. 3 It has been hypothesized that the use of ACEIs/ARBs may negatively impact on the clinical outcomes of COVID-19 patients by affecting the expression of angiotensinconverting enzyme 2 aminopeptidase (ACE-2), the human receptor for SARS-CoV-2. We searched PubMed, Scopus, and web sources up to 7 June 2020 for studies reporting data on the association between ACEI/ARB use and clinical outcomes in patients with COVID-19. When needed, the corresponding authors of the included studies were contacted, and one of them provided additional data that were not available in the original publication. In the unadjusted analysis, the use of ACEIs/ARBs was not associated with an increased risk of all-cause death (OR 0.95, 95% CI 0.57-1.58; Figure 1A ) or severe disease (OR 0.88, 95% CI 0.60-1.31). Estimation of renin-angiotensin-aldosterone-system (RAAS)-inhibitor effect on COVID-19 outcome: a meta-analysis	./cache/cord-282312-h3h6vw5l.txt	./txt/cord-282312-h3h6vw5l.txt